Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Brief Summary: This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.


Options:
A: Arm Label: Tisagenlecleucel; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: lymphodepleting chemotherapy, Drug: Bridging Therapy | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: lymphodepleting chemotherapy; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: Bridging Therapy; Assigned to Arm(s): Tisagenlecleucel
B: Arm Label: CAR T cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous 3rd generation CD19-targeting CAR T cells | Intervention Type: BIOLOGICAL; Name: Autologous 3rd generation CD19-targeting CAR T cells; Assigned to Arm(s): CAR T cells
C: Arm Label: ACTR707 in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR707, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR707; Assigned to Arm(s): ACTR707 in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR707 in combination with rituximab
D: Arm Label: 1x10^9-1x10^10+ high dose Interleukin-2; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Aldesleukin | Arm Label: 1x10^9-1x10^10 + high dose Retreat; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Aldesleukin | Arm Label: 0.5x10^7 cells/kg; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL | Arm Label: 2.5x10^6 cells/kg; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL | Arm Label: 1.0x10^6 cells/kg; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL | Arm Label: 1.0x10^6 cells/kg (Reduced chemo); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: 2.0x10^6 cells/kg (Reduced chemo); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: 6.0x10^6 cells/kg (Reduced chemo); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: 2.0x10^6 cells/kg (Moderate chemo); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: 2.0x10^6 cells/kg (9-12 days culture); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): 0.5x10^7 cells/kg, 1.0x10^6 cells/kg, 1x10^9-1x10^10 + high dose Retreat, 1x10^9-1x10^10+ high dose Interleukin-2, 2.5x10^6 cells/kg | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): 0.5x10^7 cells/kg, 1.0x10^6 cells/kg, 1x10^9-1x10^10 + high dose Retreat, 1x10^9-1x10^10+ high dose Interleukin-2, 2.5x10^6 cells/kg | Intervention Type: BIOLOGICAL; Name: Anti-cluster of differentiation 19 (CD19)-CAR PBL; Assigned to Arm(s): 0.5x10^7 cells/kg, 1.0x10^6 cells/kg, 1.0x10^6 cells/kg (Reduced chemo), 1x10^9-1x10^10 + high dose Retreat, 1x10^9-1x10^10+ high dose Interleukin-2, 2.0x10^6 cells/kg (9-12 days culture), 2.0x10^6 cells/kg (Moderate chemo), 2.0x10^6 cells/kg (Reduced chemo), 2.5x10^6 cells/kg, 6.0x10^6 cells/kg (Reduced chemo) | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): 1x10^9-1x10^10 + high dose Retreat, 1x10^9-1x10^10+ high dose Interleukin-2 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): 1.0x10^6 cells/kg (Reduced chemo), 2.0x10^6 cells/kg (9-12 days culture), 2.0x10^6 cells/kg (Moderate chemo), 2.0x10^6 cells/kg (Reduced chemo), 6.0x10^6 cells/kg (Reduced chemo) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): 1.0x10^6 cells/kg (Reduced chemo), 2.0x10^6 cells/kg (9-12 days culture), 2.0x10^6 cells/kg (Moderate chemo), 2.0x10^6 cells/kg (Reduced chemo), 6.0x10^6 cells/kg (Reduced chemo)

Answer: C